- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04027400
Effects of Computer-Assisted Cognitive Rehabilitation Programs With Breast Cancer Survivors
August 9, 2019 updated by: Texas Woman's University
Potential study participants will be recruited at breast cancer survivor support groups.
Informed consent will be obtained with a form approved by the TWU IRB and participants will complete 4 tests.
Then participants will be randomly assigned to one of two computer-assisted cognitive programs.
Participants will be sent by email, exercises specific to their assigned computer-assisted cognitive program from Happyneuron Pro (http://ie.scientificbraintrainingpro.eu/).
Cognitive training on the computer entails 30 minutes a day, five times a week for one month.
At the end of the study, the four pretests will be repeated, a satisfaction survey administered.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
Potential study participants will be recruited using a recruitment script and recruitment brochure at breast cancer survivor support groups.
Participants recruited to the study will be contacted to set up a pre-test data collection session.
Prior to any testing, informed consent will be obtained with a form approved by the TWU IRB.
After informed consent is obtained participants will complete tests of Digit Span Task, FACT-Cognitive Function (Version 3), Quality of Life Patient/Cancer Survivor Version and Engagement in Meaningful Activities Survey, and issued a tablet if they prefer.
Then participants will be randomly assigned to one of two computer-assisted cognitive programs.
Participants will be sent by email, exercises specific to their assigned computer-assisted cognitive program from Happyneuron Pro (http://ie.scientificbraintrainingpro.eu/).
Cognitive training on the computer entails 30 minutes a day, five times a week for one month.
6.
At the end of the study, the four pretests will be repeated, a satisfaction survey administered, and any issued tablets collected.
Pre and post testing, obtaining of written consent, and issuing and returning a tablet will occur at the support group location.
If this location is not available, they will occur at TWU in a quiet room.
If TWU is not convenient to the participant, a quiet location that is suitable to maintain confidentiality for the participant will be chosen in collaboration with the participant.
Study Type
Interventional
Enrollment (Anticipated)
52
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- Texas Woman's University
-
Contact:
- Theresa M Smith, PhD
- Phone Number: 504-583-0295
- Email: tsmith12@twu.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 99 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- study participant self-identifies as breast cancer survivor
- had treatment that may have included surgery, chemotherapy, radiation, pharmacological or any combination of these treatments
- participant states has cognitive problems due to cancer treatment
Exclusion Criteria:
- persons who cannot read or understand spoken English
- have disorders that may affect their cognition including major mental disorder, central nervous system disorders, Alzheimer's disease, dementia, developmental delay, traumatic brain injury, or cerebrovascular accident.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
ACTIVE_COMPARATOR: Primarily visual computer exercises
Participant performs visual computer exercises 30 minutes a day, five days a week for one month.
|
Participant is presented with 10 exercises a day, 3 minutes each.
When participant achieves 100% accuracy of the exercise, he/she gets a higher level of exercise.
Levels of range from 1-9.
Exercises are changed every week by researcher.
Other Names:
|
|
EXPERIMENTAL: Visual+Audio
Participant performs audio computer exercises and some visual computer exercises 30 minutes a day, five days a week for one month
|
Participant is presented with 10 exercises a day, 3 minutes each.
When participant achieves 100% accuracy of the exercise, he/she gets a higher level of exercise.
Levels of range from 1-9.
Exercises are changed every week by researcher.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Digit span
Time Frame: 10 minutes
|
Working memory was measured by the digit span, shown to discriminate between BCS and controls.19
It takes approximately 10 minutes to administer and has high reliability (.891) for forward span and low for backwards span (.598).
|
10 minutes
|
|
FACT-COG
Time Frame: 10 minutes
|
The FACT-COG contains 4 subscales of perceived cognitive impairment, comments from others, perceived cognitive abilities, and impact of cognition on quality of life which are summed to provide a score.
Fact-Cog demonstrates acceptable test-retest reliability (.707) and validity (.762)
|
10 minutes
|
|
CANCER PATIENT/CANCER SURVIVOR VERSION
Time Frame: 10 minutes
|
Quality of life as it relates to cancer survival, was measured with the 41 item Quality of Life Instrument (CANCER PATIENT/CANCER SURVIVOR VERSION).21
The overall QOL-CS tool test re-test reliability is .89
|
10 minutes
|
|
EMAS
Time Frame: 10 minutes
|
Frequency of engagement in meaningful activities was assessed with the Engagement in Meaningful Activities Survey (EMAS) to calculate how often a subject participates in 12 activities.
|
10 minutes
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Satisfaction Survey
Time Frame: 5 minutes
|
3 questions delivered post intervention on participant satisfaction with being in the study.
|
5 minutes
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Theresa M Smith, PhD, Associate professor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
February 26, 2018
Primary Completion (ANTICIPATED)
February 25, 2020
Study Completion (ANTICIPATED)
February 26, 2020
Study Registration Dates
First Submitted
July 17, 2019
First Submitted That Met QC Criteria
July 17, 2019
First Posted (ACTUAL)
July 22, 2019
Study Record Updates
Last Update Posted (ACTUAL)
August 13, 2019
Last Update Submitted That Met QC Criteria
August 9, 2019
Last Verified
August 1, 2019
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 19959
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage IIIB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast CancerUnited States
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
University of Colorado, DenverCompletedStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast CancerUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
National Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerCanada
-
University of Central FloridaFlorida Department of HealthRecruitingBreast Cancer | Breast Cancer Female | Breast Cancer Diagnosis | Breast Cancer Survivors | Breast Cancer Detection | Breast Cancer AwarenessUnited States
-
Mayo ClinicMarker Therapeutics, Inc.CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
Clinical Trials on computer-assisted rehabilitation
-
Selcuk UniversityEnrolling by invitationEpilepsy | Quality of Life | Computer-assisted Cognitive RehabilitationTurkey
-
Istanbul University - CerrahpasaNot yet recruitingMild Cognitive Impairment (MCI)Turkey (Türkiye)
-
University of California, San FranciscoSan Francisco Veterans Affairs Medical Center; Tobacco Related Disease Research...Completed
-
Stryker InstrumentsWithdrawnTotal Knee ArthroplastyUnited States
-
KU LeuvenCompletedMaxillofacial Abnormalities | Computer-assisted Surgery | Virtual Surgical Planning
-
Christophe FehlmannUnknownPlain Abdominal RadiographySwitzerland
-
University of AarhusCompleted
-
Queen's UniversityTerminatedAnterior Cruciate Ligament ReconstructionCanada
-
Robert Bosch Gesellschaft für Medizinische Forschung...CompletedHypertension | Diabetes | Vasculitis | Hypercholesterolemia | Coronary Heart DiseasesGermany
-
GCS Ramsay Santé pour l'Enseignement et la RechercheActive, not recruiting